Kari J. Kurppa

The paper develops a computational-experimental framework to identify mutant-selective EGFR inhibitors by leveraging paired activity measurements and structural analysis.

This study shows that DTP cells in EGFR-mutant lung cancer drive immunosuppression through YAP/TEAD activity, and co-targeting YAP/TEAD improves EGFR TKI therapy efficacy.

This study identifies recurrent ERBB4 mutations with oncogenic potential and resistance to targeted therapies, suggesting clinical implications for treatment strategies.

This study evaluates the pharmacokinetics and efficacy of tank-water administered dabrafenib in zebrafish with BRAF-mutant melanoma, showing rapid absorption, short half-life, and effective treatment with minimal toxicity.

DORM is a database of recurrent mutations in cancers, enabling search by protein, amino acid substitution, and regular expressions.